Notícias e Atividades da Gain Therapeutics

Veja o organograma con seus 18 executivos principais

Biografias mais buscadas da Gain Therapeutics

• Gene Mack, Chief Executive Officer and President
• Dov Goldstein, Independent Member
• Jeffrey Riley, Head, Biology

Recentes movimentos de executivos em Gain Therapeutics

• Maria Luisa, Human Resources and Operations Manager, deixou a Companhia  (Notícia publicada em 6 de julho de 2026).

Criar um alerta
para seguir os movimentos de executivos da Gain Therapeutics.

Gain Therapeutics possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado em 15 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Robert Gould - Board Member da Fulcrum Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Gain Therapeutics

• Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
• H.C. Wainwright Fireside Chat with President and CEO Gene Mack
• Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
• Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
• Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
• Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
• Gain Therapeutics to Present at the 38th Annual ROTH Conference
• ROTH Fireside Chat with President and CEO Gene Mack
• Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
• Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
• View more press releases Close

Redes sociais sobre Gain Therapeutics

• Gain Therapeutics na Wikipedia, Google News e Yahoo Finance
• Gain Therapeutics na LinkedIn, X (Twitter) e YouTube